Amgen Highlighting Cinacalcet Ability To Meet New Targets In Guidelines
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen’s pre-approval positioning for cinacalcet is focusing on the calcimimetic’s ability to meet the lower target mineral levels set in the National Kidney Foundation’s new guidelines for bone metabolism and disease.